BIOMAT Database Logo BIOMAT Database Logo

An oestrogen-producing seminoma responsible for gynaecomastia. 2003

C Duparc, and G Boissiere-Veverka, and H Lefebvre, and A Laquerriere, and P Vuillermet, and A Landreat, and R Ivell, and N DeRoux, and J M Kuhn
European Institute for Peptide Research (IFRMP 23), Department of Endocrinology, INSERM U 413, Boisguillaume Hospital, University Hospital of Rouen, 76031 Rouen cedex, France.

In feminising testicular tumours, oestrogens can be either secreted by the tumour itself or produced by normal Leydig cells in response to paracrine and/or endocrine stimulation by hCG. Typical hormonal Leydig cell tumour patterns include: plasma oestradiol levels > 300 pmol/l on day 3 following an hCG injection, reduced plasma testosterone, and normal plasma hCG and gonadotrophin levels. Except for elevated plasma oestradiol levels, opposite results are observed in seminomas. We report a case of oestrogen-secreting seminoma mimicking a Leydig cell tumour. A 24-year-old Caucasian patient had complained of gynaecomastia for 6 months before admission. Hormonal pattern was typical of Leydig cell tumour. A 1.4 cm tumour was found in the left testis and confirmed on sonography. Considering the likely diagnosis of Leydig cell tumour, the patient was treated by tumourectomy. Surprisingly, pathological examination revealed a pure seminoma. Perifusion experiments showed that the tumour was able to secrete significant amounts of oestradiol. In addition, hCG induced a two-fold increase in oestradiol production from perifused tumour explants. Immunohistochemistry revealed that the tumour was composed of nests of seminoma cells intermingled with lymphoid infiltrates. Tumour cells also expressed aromatase, the hCG/LH receptor and the Leydig cell marker relaxin-like factor, but were betahCG-negative. These results demonstrate that a pure seminoma of the testis is able to synthesise and secrete oestrogens. They also illustrate that the body of proof favouring the diagnosis of feminising Leydig cell tumour of the testis is not rigorously specific.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008297 Male Males
D009919 Orchiectomy The surgical removal of one or both testicles. Castration, Male,Orchidectomy,Castrations, Male,Male Castration,Male Castrations,Orchidectomies,Orchiectomies
D010477 Perfusion Treatment process involving the injection of fluid into an organ or tissue. Perfusions
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D004967 Estrogens Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds. Estrogen,Estrogen Effect,Estrogen Effects,Estrogen Receptor Agonists,Estrogenic Agents,Estrogenic Compounds,Estrogenic Effect,Estrogenic Effects,Agents, Estrogenic,Agonists, Estrogen Receptor,Compounds, Estrogenic,Effects, Estrogen,Effects, Estrogenic,Receptor Agonists, Estrogen
D006063 Chorionic Gonadotropin A gonadotropic glycoprotein hormone produced primarily by the PLACENTA. Similar to the pituitary LUTEINIZING HORMONE in structure and function, chorionic gonadotropin is involved in maintaining the CORPUS LUTEUM during pregnancy. CG consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is virtually identical to the alpha subunits of the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity (CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN). Chorionic Gonadotropin, Human,HCG (Human Chorionic Gonadotropin),Biogonadil,Choriogonadotropin,Choriogonin,Chorulon,Gonabion,Human Chorionic Gonadotropin,Pregnyl,Gonadotropin, Chorionic,Gonadotropin, Human Chorionic
D006177 Gynecomastia Enlargement of the BREAST in the males, caused by an excess of ESTROGENS. Physiological gynecomastia is normally observed in NEWBORNS; ADOLESCENT; and AGING males. Adolescent Gynecomastia,Infant Gynecomastia,Male Breast Enlargement,Newborn Gynecomastia,Breast Enlargement, Male,Enlargement, Male Breast,Gynecomastia, Adolescent,Gynecomastia, Infant,Gynecomastia, Newborn
D006728 Hormones Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various ENDOCRINE GLANDS and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects. Hormone,Hormone Receptor Agonists,Agonists, Hormone Receptor,Receptor Agonists, Hormone

Related Publications

C Duparc, and G Boissiere-Veverka, and H Lefebvre, and A Laquerriere, and P Vuillermet, and A Landreat, and R Ivell, and N DeRoux, and J M Kuhn
Gynaecomastia caused by a primary mediastinal seminoma.
April 1994, Clinical endocrinology,
C Duparc, and G Boissiere-Veverka, and H Lefebvre, and A Laquerriere, and P Vuillermet, and A Landreat, and R Ivell, and N DeRoux, and J M Kuhn
Percutaneous oestrogen- induced gynaecomastia: a case report.
April 1982, British journal of plastic surgery,
C Duparc, and G Boissiere-Veverka, and H Lefebvre, and A Laquerriere, and P Vuillermet, and A Landreat, and R Ivell, and N DeRoux, and J M Kuhn
AN OESTROGEN-SECRETING SEX-CHROMATIN-POSITIVE TERATOMA OF THE TESTIS, ASSOCIATED WITH GYNAECOMASTIA.
September 1963, The British journal of surgery,
C Duparc, and G Boissiere-Veverka, and H Lefebvre, and A Laquerriere, and P Vuillermet, and A Landreat, and R Ivell, and N DeRoux, and J M Kuhn
Prostatic adenocarcinoma with cutaneous metastases overlying oestrogen-induced gynaecomastia.
May 1998, Clinical and experimental dermatology,
C Duparc, and G Boissiere-Veverka, and H Lefebvre, and A Laquerriere, and P Vuillermet, and A Landreat, and R Ivell, and N DeRoux, and J M Kuhn
beta-HCG producing seminoma.
January 1985, Progress in clinical and biological research,
C Duparc, and G Boissiere-Veverka, and H Lefebvre, and A Laquerriere, and P Vuillermet, and A Landreat, and R Ivell, and N DeRoux, and J M Kuhn
[Management of chorionic gonadotropin-producing seminoma].
May 2011, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie,
C Duparc, and G Boissiere-Veverka, and H Lefebvre, and A Laquerriere, and P Vuillermet, and A Landreat, and R Ivell, and N DeRoux, and J M Kuhn
Phyllodes tumor in a male patient with bilateral gynaecomastia induced by oestrogen therapy for prostatic carcinoma.
April 1991, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,
C Duparc, and G Boissiere-Veverka, and H Lefebvre, and A Laquerriere, and P Vuillermet, and A Landreat, and R Ivell, and N DeRoux, and J M Kuhn
Oestrogen and cortisol producing adrenal tumour.
October 1994, Archives of disease in childhood,
C Duparc, and G Boissiere-Veverka, and H Lefebvre, and A Laquerriere, and P Vuillermet, and A Landreat, and R Ivell, and N DeRoux, and J M Kuhn
A factor in the oestrogen-treated uterus responsible for leucocyte emigration.
April 1958, The Journal of pathology and bacteriology,
C Duparc, and G Boissiere-Veverka, and H Lefebvre, and A Laquerriere, and P Vuillermet, and A Landreat, and R Ivell, and N DeRoux, and J M Kuhn
An interesting case of gynaecomastia.
January 2016, Australian family physician,
Copied contents to your clipboard!